Clinical Trial Update: BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

BRAZAN is a Phase 2 randomized trial evaluating induction with Bendamustine, Rituximab, Cytarabine plus Zanubrutinib, followed by Zanubrutinib/Rituximab with or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Cytarabine (Ara-C) (cytarabine)
• Rituximab (rituximab)
• Sonrotoclax
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Christine Ryan | Conditions: Mantle Cell Lymphoma, Lymphoma | Phase 2 | Status: RECRUITING